We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: clinical trials
MedXY News
EnglishTag

clinical trials

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
Dermatologychronic GVHDclinical trials

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

By MedXY|Jan 26, 2026

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighti

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation
Internal Medicinechronic respiratory diseaseclinical trials

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation

By MedXY|Jan 22, 2026

A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.

High-Dose Walking Booster Program: A Feasible Strategy to Overcome Rehabilitation Plateaus in Chronic Stroke
Neurologyclinical trialsneuroplasticity

High-Dose Walking Booster Program: A Feasible Strategy to Overcome Rehabilitation Plateaus in Chronic Stroke

By MedXY|Jan 21, 2026

The Phase II HiWalk trial demonstrates that a 43-hour high-intensity walking booster program is safe and feasible for chronic stroke survivors, yielding significant walking speed improvements for individuals who have already completed their

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
Hematology-Oncologyadjuvant therapyCarboplatin

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

By MedXY|Jan 20, 2026

The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers
newsclinical trialsoncology

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

By MedXY|Jan 20, 2026

Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
newsclinical trialsimmunotherapy

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

By MedXY|Jan 19, 2026

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies
Clinical Updatesclinical trialsiptacopan

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

By MedXY|Jan 19, 2026

This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics
Clinical Updatesclinical trialsGLP-1

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

By MedXY|Jan 17, 2026

This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage
Neurologyclinical trialsIntracerebral Hemorrhage

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage

By MedXY|Jan 17, 2026

While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial
Internal Medicineclinical trialsIdiopathic Pulmonary Fibrosis

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

By MedXY|Jan 13, 2026

The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Infectious Diseasesclinical trialstuberculosis

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

By MedXY|Jan 13, 2026

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression

Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors
newsclinical trialstargeted therapy

Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors

By MedXY|Jan 13, 2026

The Phase II BRISK trial demonstrates that the combination of bevacizumab and erlotinib provides significant clinical activity in patients with solid tumors harboring Krebs cycle gene mutations, particularly in FH-deficient renal cell carci

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial
newsclinical trialsoncology

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

By MedXY|Jan 13, 2026

The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer
newsclinical trialsmetastatic breast cancer

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

By MedXY|Jan 12, 2026

A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demon

Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer
newsclinical trialsprostate cancer

Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer

By MedXY|Jan 10, 2026

The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and be

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis
Clinical Updatesclinical trialsGLP-1 RA

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

By MedXY|Jan 10, 2026

This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer
newsantibody-drug conjugatesbreast cancer

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY|Jan 9, 2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre

Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results
Infectious Diseasesclinical trialsinfectious diseases

Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results

By MedXY|Dec 29, 2025

The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab

Blarcamesine in Early Alzheimer’s Disease: Promising Results Amidst Controversies
Internal MedicineAlzheimer's diseaseclinical trials

Blarcamesine in Early Alzheimer’s Disease: Promising Results Amidst Controversies

By MedXY|Dec 25, 2025

Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.

Structured Walking Protocol Boosts Post-Stroke Recovery: Insights from the Walk ‘n Watch Trial
Neurologyclinical trialsneuroplasticity

Structured Walking Protocol Boosts Post-Stroke Recovery: Insights from the Walk ‘n Watch Trial

By MedXY|Dec 23, 2025

The Walk ‘n Watch trial shows that a structured, progressive walking protocol significantly improves endurance in subacute stroke patients, providing a 43.6-meter advantage over usual care without increasing serious adverse events.

Prev
3 / 5
12345
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities